Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fulcrum Therapeutics (FULC) Cash from Operations (2019 - 2025)

Fulcrum Therapeutics (FULC) has disclosed Cash from Operations for 7 consecutive years, with 16798000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Cash from Operations changed 0.22% to 16798000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was 60065000.0, a 2608.07% decrease, with the full-year FY2025 number at 60065000.0, down 2608.07% from a year prior.
  • Cash from Operations was 16798000.0 for Q4 2025 at Fulcrum Therapeutics, down from 14190000.0 in the prior quarter.
  • In the past five years, Cash from Operations ranged from a high of 58899000.0 in Q2 2024 to a low of 27882000.0 in Q3 2022.
  • A 5-year average of 16438800.0 and a median of 20240500.0 in 2022 define the central range for Cash from Operations.
  • Peak YoY movement for Cash from Operations: crashed 401.18% in 2021, then surged 383.37% in 2024.
  • Fulcrum Therapeutics' Cash from Operations stood at 21858000.0 in 2021, then rose by 9.89% to 19696000.0 in 2022, then decreased by 17.58% to 23158000.0 in 2023, then grew by 27.62% to 16761000.0 in 2024, then decreased by 0.22% to 16798000.0 in 2025.
  • Per Business Quant, the three most recent readings for FULC's Cash from Operations are 16798000.0 (Q4 2025), 14190000.0 (Q3 2025), and 13820000.0 (Q2 2025).